首页> 外文OA文献 >A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples.
【2h】

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples.

机译:乳腺癌核心穿刺活检样品中雌激素受体-染色质相互作用的载体辅助ChIP-seq方法。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: The Estrogen Receptor alpha (ERalpha) is the key transcriptional regulator in luminal breast cancer and is therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the transcriptional capacities of ERalpha, which are a direct consequence of the receptors binding preference at specific sites on the chromatin. The identification of ERalpha binding signatures on a genome-wide level has greatly enhanced our understanding of Estrogen Receptor biology in cell lines and tumours, but the technique has its limitations with respect to its applicability in limited amounts of tumour tissue. RESULTS: Here, we present a refinement of the ChIP-seq procedures to enable transcription factor mapping on limited amounts of tissue culture cells as well as from a limited amount of tumor tissue derived from core needle biopsies. Our approach uses a carrier that can be removed prior to DNA amplification and sequencing. CONCLUSION: We illustrate the applicability of this refined technology by mapping the ERalpha genome-wide chromatin binding landscape in core needle biopsy material from primary breast tumours. With this, our refined technology permits for a high-resolution transcription factor mapping even from clinical samples.
机译:背景:雌激素受体α(ERalpha)是管腔型乳腺癌的关键转录调节因子,因此是该亚型辅助治疗的主要靶标。发光基因签名由ERalpha的转录能力决定,这是染色质上特定位点受体结合偏好的直接结果。在全基因组水平上对ERalpha结合特征的鉴定大大增强了我们对细胞系和肿瘤中雌激素受体生物学的了解,但是该技术在其在有限数量的肿瘤组织中的适用性方面有其局限性。结果:在这里,我们提出了ChIP-seq程序的改进,可以在有限数量的组织培养细胞上以及从有限数量的源自芯针活检组织的肿瘤组织中进行转录因子作图。我们的方法使用的载体可以在DNA扩增和测序之前除去。结论:我们通过绘制来自原发性乳腺肿瘤的核心针穿刺活检材料中的ERalpha全基因组染色质结合图谱来说明这种改良技术的适用性。这样,我们完善的技术甚至可以从临床样品中获得高分辨率的转录因子图谱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号